Board documents
02-03 July 2026

Board Meeting 50

Ministere de l'Europe et des Affaires étrangères, Paris, France

Resolutions:

R1 - Development of Unitaid's Next Strategy
R2 - Introduction of a Reinforcements Pathway within Unltald's Operating Model
R3 - Area for Intervention "Integrated care for small and vulnerable newborns"
R4 - Area for Intervention "Demonstrating people-centered, cost-effective care for tuberculosis and hepatitis C in key and vulnerable populations in high-transmission settings"
R5 - Audited Financial Statements for 2025 and Report of the External Auditor
R6 - Board Operating Procedures
R7 - Renewal of the Governance Working Group mandate
R8 - Extension of term of the Vice-Chair of the Executive Board
R9 - Extension of appointments of the Chairs and Vice-Chairs of the Policy and Strategy Committee and the Finance and Accountability Committee
R10 - Extension of appointment of the Members of the Policy and Strategy Committee and the Finance and Accountability Committee
R11 - Extension of appointment of the Chair, Vice-Chair and Members of the Governance Working Group
10-11 December 2025

Board Meeting 48

Tokyo, Japan

Resolutions:

R1 - Mid-Term Review of 2023-2027 Strategy
R2 - Additional funding for Community and Civil Society Engagement (CCSE)
R3 - Additional funding for Country Stakeholder Engagement (CSE)
R4 - Selection of the Proposal Review Committee Vice-Chair
R6 - Approval of revisions to the KPI framework
R7 - Next-Generation Financing
R8 - Approval of the 2026 Unitaid Budget
R9 - Revision of the African Constituency Budget for 2025
R10 - Revision of the Communities Constituency Budget for 2025
R11 - Renewal of the GWG mandate, leadership and membership
R12 - Extension of term of the Vice-Chair of the Executive Board

Documents:

Minutes from the 46th meeting of the Executive Board 11-12 June 2025
Report from the Executive Director
Review of the performance framework (including KPIs)
Provisional Agenda
Unitaid Secretariat Management Response to the Unitaid 2023-2027. Strategy Mid-Term Review
Mid-Term Review (MTR) of Unitaid’s 2023-2027 Strategy. Technical Annex
Mid-Term Review (MTR) of Unitaid’s 2023-2027 Strategy. Summary Report
11-12 June 2025

Board Meeting 46

The Forum, Global Health Campus Geneva, Switzerland

Minutes:

Resolutions:

R1 - Audited Financial Statements for 2024 and Report of the External Auditor
R2 - Proposal Review Committee replenishment
R3 - Proposal Review Committee leadership selection and performance assessment process

Documents:

Provisional Agenda
Report from the Executive Director
2023-2027 Strategy – Key Performance Indicator report (June 2025)
Audited financial statements for the year ended 31 December 2024
Proposal Review Committee replenishment
Proposal Review Committee Terms of Reference
02-05 December 2024

Board Meeting 45

Johannesburg, South Africa

Resolutions:

R1 - Implementation of the Functional Review
R2 - Area for Intervention "Climate & Health"
R3 - Amendment of PRC Terms of Reference
R4 - Approval of the 2025 Unitaid Budget

Documents:

Minutes from the 44th meeting of the Executive Board, 18-19 June 2024
Provisional Agenda
Report from the Executive Director
Area for Intervention: Support and accelerate the transition towards climate-smart health products
Proposal Review Committee. Terms of Reference
Proposed changes to the PRC composition and areas of expertise
18-19 June 2024

Board Meeting 44

Global Health Campus Geneva, Switzerland

Resolutions:

R11 - Extension of invitation to Japan to occupy the Temporary Executive Board Seat
R10 - Extension of appointment of the Members of the Policy and Strategy Committee and the Finance and Accountability Committee
R9 - Extension of appointment of the Chairs and Vice-Chairs of the Policy and Strategy Committee and the Finance and Accountability Committee
R8 - Amendments to the Code of Ethical Conduct for Unitaid Board Constituencies and Governance Officials
R7 - Audited Financial Statements for 2023 and Report of the External Auditor
R6 - Area for Intervention “Regional Manufacturing for Equitable Access” (RMEA}
R5 - Area for Intervention “Improving people-centred care through integrated diagnostic tools and delivery approaches”
R4 - Area for Intervention “Improving access to innovations in sustainable oxygen production, distribution and supply”
R3 - Area for Intervention “Improving risk detection and management of pre-eclampsia”
R2 - Area for Intervention “Improving access to care for moderate and severe anaemia in vulnerable groups in LMICs”
R1 - Functional Review

Documents:

Provisional Agenda
Minutes from the 43rd meeting of the Executive Board
Report from the Executive Director
2023-2027 Strategy – Key Performance Indicator report (June 2024)
Area for Intervention: Improving access to care for moderate and severe anaemia in vulnerable groups in LMICs
Area for Intervention: Improving risk detection and management of pre-eclampsia
Area for Intervention: Improving access to innovations in sustainable oxygen production, distribution, and supply
Area for Intervention: Improving people-centered care through integrated diagnostic tools and delivery approaches
Area for Intervention: Regional Manufacturing for Equitable Access (RMEA)
Audited financial statements 2023
Report of the external auditor 2023
Code of Ethical Conduct for Unitaid Board Constituencies and Governance Officials
21-22 November 2023

Board Meeting 43

Brasilia, Brazil

Resolutions:

R9 - Policy for the acceptance of Specified Contributions
R8 - Revisions to 2022 Operating Budget
R7 - Revisions to 2023 Operating Budget
R6 - Approval of the 2024 Unitaid Budget
R5 - Climate and Health Strategy
R4 - Area for Intervention: Enabling access to monoclonal antibodies to treat and prevent infectious diseases in LMICs
R3 - Extension of term of the Unitaid Board Vice-Chair
R2 - Extension of term of the Unitaid Board Chair
R1 - Approval of revisions to the KPI framework

Documents:

Provisional Agenda
Minutes from the 42nd meeting of the Executive Board
Annex 1: Exchange of letters between Board Chair and Executive Director
Annex 2: Executive Director Report on Objectives
Report from the Executive Director
Annex A: Key Performance Indicator report, Mission Strategic Objective KPIs
Annex B: Key Performance Indicator report Organizational KPIs
Policy for acceptance of Specified Contributions
Area for Intervention: Enable access to monoclonal antibodies to treat and prevent infectious diseases in LMICs
Annex: Climate and Health Strategy Performance Framework
Climate and Health Strategy
14-15 June 2023

Board Meeting 42

Global Health Campus Geneva, Switzerland

Resolutions:

R7 - Scheduling of the 43rd Executive Board meeting
R6 - Unitaid Commitment Policy
R5 - Audited Financial Statements for 2022 and Report of the External Auditor
R4 - Renewal of the appointments of the Chair and appointment of the Vice Chair of the Proposal Review Committee
R3 - Unitaid Functional Review
R2 - Area for Intervention: Accelerate access to tools to drive Elimination of Mother-to-Child Transmission (EMTCT) of HIV, syphilis, and hepatitis B, including Chagas in endemic areas
R1 - Area for Intervention: Accelerate and promote responsible introduction of new DR-TB drugs and regimens

Documents:

Provisional Agenda
Minutes of the 41th Session of the Executive Board
Report from the Executive Director
Area for Intervention: Accelerate and promote responsible introduction of new DR-TB drugs and regimens
Area for Intervention: Accelerate access to tools to drive Elimination of Mother-to-Child Transmission (EMTCT) of HIV, syphilis, and hepatitis B, including Chagas in endemic areas
Audited Financial Statements 2022
Commitment Policy
05-06 December 2022

Board Meeting 41

Global Health Campus Geneva, Switzerland

Resolutions:

R3 - Extension of the invitation to Japan to occupy the temporary Executive Board seat
R2 - Approval of the 2023 Unitaid Budget
R1 - Area for Intervention: “Mitigating antimalarial drug resistance”

Documents:

Provisional Agenda
Report from the Executive Director
2023: Proposed Operating Expenses Budget
Area for Intervention: Mitigating antimalarial drug resistance in Africa (Malaria Programmatic Priority: Improve access to quality case management)
1 2 3 … 7

2026

July

R18-2026-e

Reprogramming for the CANVeCT Project

R17-2026-e

Country Operationalized Novel Vector Interventions for Malaria Control (CONVINCE)

R16-2026-e

Cost Extension for the Project “Sustainable Community-driven Approaches for Lenacapavir PrEP Expansion with Impact in Zambia” (SCALE-IT Zambia)

R15-2026-e

Cost Extension for the Project “Integrating PrEP into Comprehensive Services for Adolescent Girls and Young Women”

R14-2026-e

Cost Extension of the Project “Solidarity Access Project for Medical Products Using TRIPS flexibilities in LMICs”

R13-2036-e

No-Cost Extension for the Project “Adherence Support Coalition to End TB” (ASCENT)

June

R12-2026-e

Ebola Bundibugyo Response (PPPR)

R11-2026-e

Reprogramming for the SAFEStart+ Project

1 2 3 … 34

Code of ethical conduct for Unitaid board constituencies and governance officials

Unitaid constitution

Board operating procedures